YM 529

YM-529 is a third-generation bisphosphonate drug that is primarily used in the treatment of osteoporosis. It is also known as minodronic acid and is marketed under the brand name Recalbon in Japan.

Mechanism of Action[edit | edit source]

YM-529 works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption. This results in an overall decrease in bone turnover, which can help to prevent bone loss and increase bone density.

Clinical Use[edit | edit source]

YM-529 is used in the treatment of osteoporosis, a condition characterized by low bone mass and deterioration of bone tissue. This can lead to increased bone fragility and risk of fracture. YM-529 is also used in the treatment of Paget's disease, a condition that disrupts the normal cycle of bone renewal, leading to bones becoming enlarged and weakened.

Side Effects[edit | edit source]

Common side effects of YM-529 include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, it can cause more serious side effects such as osteonecrosis of the jaw and atypical femoral fractures.

Pharmacokinetics[edit | edit source]

YM-529 is administered orally and is rapidly absorbed in the gastrointestinal tract. It has a high affinity for bone tissue and is excreted primarily in the urine.

Research[edit | edit source]

Several studies have shown that YM-529 is effective in increasing bone mineral density and reducing the risk of fractures in patients with osteoporosis. It has also been shown to be effective in the treatment of Paget's disease.